• +1-646-491-9876
    • +91-20-67278686

    Search

    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 Receptor Subunit Alpha 5 or GABRA5 Pipeline Review H1 2017

    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 Receptor Subunit Alpha 5 or GABRA5 Pipeline Review H1 2017

    • Report Code ID: RW0001858685
    • Category Pharmaceuticals
    • No. of Pages 31
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Pipeline Review, H1 2017

    Summary

    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Gamma-aminobutyric acid A receptor, alpha 5 or GABRA5 is a protein encoded by the GABRA5 gene. it , mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.

    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Alzheimer's Disease, Autism, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS) , Depression, Ischemic Cerebral Stroke, Ischemic Stroke, Mild Cognitive Impairment, Schizophrenia and Traumatic Brain Injury.

    The latest report Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H1 2017, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5)
    - The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Overview
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Companies Involved in Therapeutics Development
    AgeneBio Inc
    F. Hoffmann-La Roche Ltd
    Les Laboratoires Servier SAS
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Drug Profiles
    AVL-8168 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    basmisanil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PWZ-029 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-44819 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize GABA Alpha 5 for Cognitive Impairment - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize GABRA5 for Depression - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Dormant Products
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Discontinued Products
    Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Product Development Milestones
    Featured News & Press Releases
    Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AgeneBio Inc, H1 2017
    Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Pipeline by Les Laboratoires Servier SAS, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AgeneBio Inc
    F. Hoffmann-La Roche Ltd
    Les Laboratoires Servier SAS

    Request for Sample

    Report Url http://www.reportsweb.com//gamma-aminobutyric-acid-receptor-subunit-alpha-5-receptor-subunit-alpha-5-or-gabra5-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//gamma-aminobutyric-acid-receptor-subunit-alpha-5-receptor-subunit-alpha-5-or-gabra5-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//gamma-aminobutyric-acid-receptor-subunit-alpha-5-receptor-subunit-alpha-5-or-gabra5-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments